Categories: BioTechBuildingDataDrugHealthTechLifeMedtechPlatformProductResearch
Aurealis Therapeutics is a Swiss-Nordic Cell and Gene Therapy Platform Company. Our multi-target cell and gene therapy platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation. After successfully completing our Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead clinical product AUP-16, we are initiating our Phase 2 study in Italy, Germany and Poland, first for DFU. Venous Ulcers and Pressure Ulcers will follow. In Oncology, we are building on impressive pre-clinical data with Oncolytic Bacteria lead candidate AUP-55, which shows increased survival in Ovarian Cancer and peritoneal carcinomatosis. Our pipeline also includes Inflammation, at discovery stage.
Location: Finland, Mainland Finland, Kuopio
Investors 1
Mentions in press and media 12
| Date | Title | Description | Source |
| 11.03.2024 | Aurealis Therapeutics completes 50% patient recruitment for ... | Aurealis Therapeutics
AUP-16 4-in-1 Bacterial Vector for Chronic Wounds
Half of the patients expecte... | einpresswi... |
| 27.02.2024 | Aurealis Therapeutics’ lead candidate AUP-16 for chronic wou... | AUP-16 multi-target cell & gene therapy for Chronic Wounds
Aurealis Therapeutics receives PRIME ... | einpresswi... |
| 08.08.2023 | Aurealis Therapeutics Announces First Patient Dosed in DIAME... | Aurealis Therapeutics
AUP-16 4-in-1 Bacterial Vector for Chronic Wounds
BASEL, BASEL-STADT, SWITZERL... | einpresswi... |
| 05.06.2023 | A significant number of Swiss biotechs exhibit in Boston | | startuptic... |
| 10.05.2023 | Biotech startups turn gear into Phase 2 clinical trials | | startuptic... |
| 09.05.2023 | Aurealis Therapeutics receives CTA approval for AUP-16 Phase... | Aurealis Therapeutics
AUP-16 4-in-1 Bacterial Vector for Chronic Wounds
Multi-center, randomized, pl... | einpresswi... |
| 04.04.2023 | Aurealis Therapeutics banks $10 million in an oversubscribed... | | startuptic... |
| 31.01.2022 | Aurealis to receive up to $139 million in collaboration agre... | | startuptic... |
| 29.01.2022 | Aurealis Therapeutics and Xbiome Enter into a License and Co... | BASEL, Switzerland, KUOPIO, Finland, and SHENZHEN, China, Jan. 29, 2022 /PRNewswire/ -- Aurealis The... | en.prnasia... |
| 12.02.2020 | Aurealis Therapeutics startet 1-2A-Studie | | startuptic... |
| 12.02.2020 | Aurealis Therapeutics startet 1-2A-Studie | Die fortschrittliche Wundversorgung ist schon heute ein Markt mit einem jährlichen Volumen von 15 Mi... | startuptic... |
| - | Aurealis Therapeutics | “A game changer for chronic wounds, cancer, inflammatory diseases and beyond. Multi-target cell and ... | fastfounde... |
Show more
Reviews 0
